European Organisation for Research and Treatment of Cancer
@eortc.org
We define better treatments for all cancer patients to prolong survival and improve quality of life.
Pinned
📅 Get ready to make the most of EORTC’s upcoming events!
Mark your calendars 👇
#CancerResearch #ClinicalTrials #Oncology #EORTCevents #PatientDays #EBCC15 #Stats2026 #MCCRworkshop #ENASymp26
Mark your calendars 👇
#CancerResearch #ClinicalTrials #Oncology #EORTCevents #PatientDays #EBCC15 #Stats2026 #MCCRworkshop #ENASymp26
Every patient is important.
➡️Today we launch #NoPatientLeftBehind. From rare cancers to optimised treatments, help us drive real-world clinical research impact for those who need it most.
🔗 Support research that puts patients first: donate.eortcresearchfund.org/eoy/
#CancerCareForAll
➡️Today we launch #NoPatientLeftBehind. From rare cancers to optimised treatments, help us drive real-world clinical research impact for those who need it most.
🔗 Support research that puts patients first: donate.eortcresearchfund.org/eoy/
#CancerCareForAll
November 13, 2025 at 4:17 PM
Every patient is important.
➡️Today we launch #NoPatientLeftBehind. From rare cancers to optimised treatments, help us drive real-world clinical research impact for those who need it most.
🔗 Support research that puts patients first: donate.eortcresearchfund.org/eoy/
#CancerCareForAll
➡️Today we launch #NoPatientLeftBehind. From rare cancers to optimised treatments, help us drive real-world clinical research impact for those who need it most.
🔗 Support research that puts patients first: donate.eortcresearchfund.org/eoy/
#CancerCareForAll
👏 Earlier today at ISPOR Europe, our CEO Denis Lacombe moderated the plenary session “Pragmatic Trials — Bridging Research and Real-World Care”.
🔗 Read more: www.eortc.org/blog/2025/11...
#ISPOR #ClinicalResearch #EORTC #CancerCare #PragmaticTrials
🔗 Read more: www.eortc.org/blog/2025/11...
#ISPOR #ClinicalResearch #EORTC #CancerCare #PragmaticTrials
November 11, 2025 at 11:15 AM
👏 Earlier today at ISPOR Europe, our CEO Denis Lacombe moderated the plenary session “Pragmatic Trials — Bridging Research and Real-World Care”.
🔗 Read more: www.eortc.org/blog/2025/11...
#ISPOR #ClinicalResearch #EORTC #CancerCare #PragmaticTrials
🔗 Read more: www.eortc.org/blog/2025/11...
#ISPOR #ClinicalResearch #EORTC #CancerCare #PragmaticTrials
🤝 We would like to thank all our contributors and supporters for the incredible support of Patient Days 2025, which took place last week.
Your engagement made it a truly meaningful event for everyone involved.
#PatientDays #EORTC
Your engagement made it a truly meaningful event for everyone involved.
#PatientDays #EORTC
November 10, 2025 at 2:47 PM
🤝 We would like to thank all our contributors and supporters for the incredible support of Patient Days 2025, which took place last week.
Your engagement made it a truly meaningful event for everyone involved.
#PatientDays #EORTC
Your engagement made it a truly meaningful event for everyone involved.
#PatientDays #EORTC
📢 EORTC is proud to join ISPOR Europe 2025!
CEO Denis Lacombe will moderate the plenary: “Pragmatic Trials — Bridging Research and Real-World Care”.
Posters by Fabio Borges, Maria Teixeira & Claire Piccinin.
🔗 www.eortc.org/blog/2025/11...
#HEOR #ClinicalTrials #ISPOREurope
CEO Denis Lacombe will moderate the plenary: “Pragmatic Trials — Bridging Research and Real-World Care”.
Posters by Fabio Borges, Maria Teixeira & Claire Piccinin.
🔗 www.eortc.org/blog/2025/11...
#HEOR #ClinicalTrials #ISPOREurope
November 10, 2025 at 12:15 PM
📢 EORTC is proud to join ISPOR Europe 2025!
CEO Denis Lacombe will moderate the plenary: “Pragmatic Trials — Bridging Research and Real-World Care”.
Posters by Fabio Borges, Maria Teixeira & Claire Piccinin.
🔗 www.eortc.org/blog/2025/11...
#HEOR #ClinicalTrials #ISPOREurope
CEO Denis Lacombe will moderate the plenary: “Pragmatic Trials — Bridging Research and Real-World Care”.
Posters by Fabio Borges, Maria Teixeira & Claire Piccinin.
🔗 www.eortc.org/blog/2025/11...
#HEOR #ClinicalTrials #ISPOREurope
🤝 As we close #PatientDays 2025, we reflect on the powerful exchanges that took place.
This event reaffirmed the importance of integrating patient perspectives into research and care.
Thank you to all who contributed to this meaningful dialogue.
#CancerResearch #ClinicalTrials
This event reaffirmed the importance of integrating patient perspectives into research and care.
Thank you to all who contributed to this meaningful dialogue.
#CancerResearch #ClinicalTrials
November 7, 2025 at 3:41 PM
🤝 As we close #PatientDays 2025, we reflect on the powerful exchanges that took place.
This event reaffirmed the importance of integrating patient perspectives into research and care.
Thank you to all who contributed to this meaningful dialogue.
#CancerResearch #ClinicalTrials
This event reaffirmed the importance of integrating patient perspectives into research and care.
Thank you to all who contributed to this meaningful dialogue.
#CancerResearch #ClinicalTrials
🎉 What a day at #EORTC #PatientDays!
Day 1 was packed with energy, empathy and honest round table talks.
Thanks to all who joined, your voices are shaping the future of cancer care.
👋 See you tomorrow!
🔗https://www.eortc.org/event/patient-days-2025/?tab=1
#CancerCare #PatientEngagement #Oncology
Day 1 was packed with energy, empathy and honest round table talks.
Thanks to all who joined, your voices are shaping the future of cancer care.
👋 See you tomorrow!
🔗https://www.eortc.org/event/patient-days-2025/?tab=1
#CancerCare #PatientEngagement #Oncology
November 6, 2025 at 4:15 PM
🎉 What a day at #EORTC #PatientDays!
Day 1 was packed with energy, empathy and honest round table talks.
Thanks to all who joined, your voices are shaping the future of cancer care.
👋 See you tomorrow!
🔗https://www.eortc.org/event/patient-days-2025/?tab=1
#CancerCare #PatientEngagement #Oncology
Day 1 was packed with energy, empathy and honest round table talks.
Thanks to all who joined, your voices are shaping the future of cancer care.
👋 See you tomorrow!
🔗https://www.eortc.org/event/patient-days-2025/?tab=1
#CancerCare #PatientEngagement #Oncology
This November, the EORTC Cancer Research Fund is putting patients at the heart of research.
From rare cancers to treatment optimisation, no patient is left behind.
Learn more: eortcresearchfund.org
#LeavingNoCancerPatientBehind
From rare cancers to treatment optimisation, no patient is left behind.
Learn more: eortcresearchfund.org
#LeavingNoCancerPatientBehind
November 6, 2025 at 1:46 PM
This November, the EORTC Cancer Research Fund is putting patients at the heart of research.
From rare cancers to treatment optimisation, no patient is left behind.
Learn more: eortcresearchfund.org
#LeavingNoCancerPatientBehind
From rare cancers to treatment optimisation, no patient is left behind.
Learn more: eortcresearchfund.org
#LeavingNoCancerPatientBehind
🤝 EORTC #PatientDays kicks off today in Brussels!
Patients, caregivers & advocates meet Europe’s top cancer researchers to shape better treatment, care & quality of life.
🔗 Learn more: www.eortc.org/event/patien...
#CancerResearch #Oncology #ClinicalTrials
Patients, caregivers & advocates meet Europe’s top cancer researchers to shape better treatment, care & quality of life.
🔗 Learn more: www.eortc.org/event/patien...
#CancerResearch #Oncology #ClinicalTrials
November 6, 2025 at 9:01 AM
🤝 EORTC #PatientDays kicks off today in Brussels!
Patients, caregivers & advocates meet Europe’s top cancer researchers to shape better treatment, care & quality of life.
🔗 Learn more: www.eortc.org/event/patien...
#CancerResearch #Oncology #ClinicalTrials
Patients, caregivers & advocates meet Europe’s top cancer researchers to shape better treatment, care & quality of life.
🔗 Learn more: www.eortc.org/event/patien...
#CancerResearch #Oncology #ClinicalTrials
📢 New insights from PEACE-1
This post-hoc analysis examines how adjusting for abiraterone-prednisone cross-over impacts survival outcomes in de novo mCSPC.
A key step in refining trial interpretation.
🔗 Read more: www.eortc.org/publications/
#PEACE1 #ProstateCancer #ClinicalTrials #EORTC
This post-hoc analysis examines how adjusting for abiraterone-prednisone cross-over impacts survival outcomes in de novo mCSPC.
A key step in refining trial interpretation.
🔗 Read more: www.eortc.org/publications/
#PEACE1 #ProstateCancer #ClinicalTrials #EORTC
November 4, 2025 at 2:12 PM
📢 New insights from PEACE-1
This post-hoc analysis examines how adjusting for abiraterone-prednisone cross-over impacts survival outcomes in de novo mCSPC.
A key step in refining trial interpretation.
🔗 Read more: www.eortc.org/publications/
#PEACE1 #ProstateCancer #ClinicalTrials #EORTC
This post-hoc analysis examines how adjusting for abiraterone-prednisone cross-over impacts survival outcomes in de novo mCSPC.
A key step in refining trial interpretation.
🔗 Read more: www.eortc.org/publications/
#PEACE1 #ProstateCancer #ClinicalTrials #EORTC
🎥 A highlight during #PinkOctober: Behind the scenes with the EORTC Breast Cancer Group.
Watch the full video now 👉 youtu.be/uRqBvA9wpig
For more info visit www.eortc.org/research_fie...
#BreastCancerAwarenessMonth #EORTCBreast #CancerResearch #ClinicalTrials #Oncology
Watch the full video now 👉 youtu.be/uRqBvA9wpig
For more info visit www.eortc.org/research_fie...
#BreastCancerAwarenessMonth #EORTCBreast #CancerResearch #ClinicalTrials #Oncology
#PinkOctober: Behind the scenes with the EORTC Breast Cancer Group.
YouTube video by EORTC
youtu.be
October 31, 2025 at 2:37 PM
🎥 A highlight during #PinkOctober: Behind the scenes with the EORTC Breast Cancer Group.
Watch the full video now 👉 youtu.be/uRqBvA9wpig
For more info visit www.eortc.org/research_fie...
#BreastCancerAwarenessMonth #EORTCBreast #CancerResearch #ClinicalTrials #Oncology
Watch the full video now 👉 youtu.be/uRqBvA9wpig
For more info visit www.eortc.org/research_fie...
#BreastCancerAwarenessMonth #EORTCBreast #CancerResearch #ClinicalTrials #Oncology
📢New in Lung Cancer Journal!
A pan-European panel led by the #EORTClung reviews 105 clinical cases to define resectable stage III NSCLC for trial inclusion.
This consensus aims to improve patient selection and trial consistency across Europe.
🔗Read here: www.eortc.org/publications/
A pan-European panel led by the #EORTClung reviews 105 clinical cases to define resectable stage III NSCLC for trial inclusion.
This consensus aims to improve patient selection and trial consistency across Europe.
🔗Read here: www.eortc.org/publications/
October 30, 2025 at 2:38 PM
📢New in Lung Cancer Journal!
A pan-European panel led by the #EORTClung reviews 105 clinical cases to define resectable stage III NSCLC for trial inclusion.
This consensus aims to improve patient selection and trial consistency across Europe.
🔗Read here: www.eortc.org/publications/
A pan-European panel led by the #EORTClung reviews 105 clinical cases to define resectable stage III NSCLC for trial inclusion.
This consensus aims to improve patient selection and trial consistency across Europe.
🔗Read here: www.eortc.org/publications/
📢 Join our team in #Brussels!
The EORTC Projects and Services department is looking for a Project Manager.
Do you have a master’s degree, a 5-year experience in a project management role and are you looking for a new challenge?
👉 Apply now: www.eortc.org/job/project-...
#Jobs
The EORTC Projects and Services department is looking for a Project Manager.
Do you have a master’s degree, a 5-year experience in a project management role and are you looking for a new challenge?
👉 Apply now: www.eortc.org/job/project-...
#Jobs
October 29, 2025 at 11:23 AM
📢 Join our team in #Brussels!
The EORTC Projects and Services department is looking for a Project Manager.
Do you have a master’s degree, a 5-year experience in a project management role and are you looking for a new challenge?
👉 Apply now: www.eortc.org/job/project-...
#Jobs
The EORTC Projects and Services department is looking for a Project Manager.
Do you have a master’s degree, a 5-year experience in a project management role and are you looking for a new challenge?
👉 Apply now: www.eortc.org/job/project-...
#Jobs
📢 New publication alert!
EORTC’s RENALUT trial explores [177Lu]Lu-PSMA-617 in metastatic ccRCC. The protocol summary is now out in European Urology Oncology, highlighting radioligand therapy’s potential.
🔗 www.eortc.org/publications/
#EORTC #RENALUT #ccRCC
EORTC’s RENALUT trial explores [177Lu]Lu-PSMA-617 in metastatic ccRCC. The protocol summary is now out in European Urology Oncology, highlighting radioligand therapy’s potential.
🔗 www.eortc.org/publications/
#EORTC #RENALUT #ccRCC
October 24, 2025 at 2:23 PM
📢 New publication alert!
EORTC’s RENALUT trial explores [177Lu]Lu-PSMA-617 in metastatic ccRCC. The protocol summary is now out in European Urology Oncology, highlighting radioligand therapy’s potential.
🔗 www.eortc.org/publications/
#EORTC #RENALUT #ccRCC
EORTC’s RENALUT trial explores [177Lu]Lu-PSMA-617 in metastatic ccRCC. The protocol summary is now out in European Urology Oncology, highlighting radioligand therapy’s potential.
🔗 www.eortc.org/publications/
#EORTC #RENALUT #ccRCC
Reposted by European Organisation for Research and Treatment of Cancer
👏 Today & tomorrow at #ISOQOL 2025, @eortc.org #QualityofLife Group & colleagues will present 4 posters, exploring topics like ePRO implementation, side-effect burden measurement, and creating the PRO-AE inventory.
🔍 Learn more: www.eortc.org/blog/2025/10...
#GivingVoice2Patients #CancerResearch
🔍 Learn more: www.eortc.org/blog/2025/10...
#GivingVoice2Patients #CancerResearch
October 24, 2025 at 12:31 PM
👏 Today & tomorrow at #ISOQOL 2025, @eortc.org #QualityofLife Group & colleagues will present 4 posters, exploring topics like ePRO implementation, side-effect burden measurement, and creating the PRO-AE inventory.
🔍 Learn more: www.eortc.org/blog/2025/10...
#GivingVoice2Patients #CancerResearch
🔍 Learn more: www.eortc.org/blog/2025/10...
#GivingVoice2Patients #CancerResearch
Reposted by European Organisation for Research and Treatment of Cancer
📣 Exciting news! @eortc.org, through its #QualityofLife (QoL) Group, is supporting #ISOQOL 2025 and will share insights into its latest QoL research through a series of impactful abstracts presented at the conference.
Learn more 👇
www.eortc.org/blog/2025/10...
#GivingVoice2Patients #CancerResearch
Learn more 👇
www.eortc.org/blog/2025/10...
#GivingVoice2Patients #CancerResearch
October 22, 2025 at 1:11 PM
📣 Exciting news! @eortc.org, through its #QualityofLife (QoL) Group, is supporting #ISOQOL 2025 and will share insights into its latest QoL research through a series of impactful abstracts presented at the conference.
Learn more 👇
www.eortc.org/blog/2025/10...
#GivingVoice2Patients #CancerResearch
Learn more 👇
www.eortc.org/blog/2025/10...
#GivingVoice2Patients #CancerResearch
🙌 That’s a wrap on #ESMO25!
EORTC shared new results and future trials focused on patient needs, long-term outcomes & treatment optimisation.
Thanks to all collaborators and patients who make this work possible.
🔗 Full summary: www.eortc.org/blog/2025/10...
#CancerResearch #ClinicalTrials
EORTC shared new results and future trials focused on patient needs, long-term outcomes & treatment optimisation.
Thanks to all collaborators and patients who make this work possible.
🔗 Full summary: www.eortc.org/blog/2025/10...
#CancerResearch #ClinicalTrials
October 21, 2025 at 7:38 AM
🙌 That’s a wrap on #ESMO25!
EORTC shared new results and future trials focused on patient needs, long-term outcomes & treatment optimisation.
Thanks to all collaborators and patients who make this work possible.
🔗 Full summary: www.eortc.org/blog/2025/10...
#CancerResearch #ClinicalTrials
EORTC shared new results and future trials focused on patient needs, long-term outcomes & treatment optimisation.
Thanks to all collaborators and patients who make this work possible.
🔗 Full summary: www.eortc.org/blog/2025/10...
#CancerResearch #ClinicalTrials
📢 Today is #WorldStatisticsDay, a moment to reflect on the tools that shape clinical research and medical progress.
Do you feel p-values satisfy the needs of clinical research in summarizing proof?
💬 Drop your thoughts in the comments, we’re reading!
Know more: www.eortc.org/blog/2025/10...
Do you feel p-values satisfy the needs of clinical research in summarizing proof?
💬 Drop your thoughts in the comments, we’re reading!
Know more: www.eortc.org/blog/2025/10...
October 20, 2025 at 9:42 AM
📢 Today is #WorldStatisticsDay, a moment to reflect on the tools that shape clinical research and medical progress.
Do you feel p-values satisfy the needs of clinical research in summarizing proof?
💬 Drop your thoughts in the comments, we’re reading!
Know more: www.eortc.org/blog/2025/10...
Do you feel p-values satisfy the needs of clinical research in summarizing proof?
💬 Drop your thoughts in the comments, we’re reading!
Know more: www.eortc.org/blog/2025/10...
Reposted by European Organisation for Research and Treatment of Cancer
👏 Congratulations to our @eortc.org #QualityofLife Group members Veronika Engele & Louis Fox for their great presentations at #ESMO25.
🏅 And well done Veronika Engele for winning the ESMO 2025 Best Poster for Psycho-oncology! 💪
#CancerResearch #GivingVoice2Patients
@kingscollegelondon.bsky.social
🏅 And well done Veronika Engele for winning the ESMO 2025 Best Poster for Psycho-oncology! 💪
#CancerResearch #GivingVoice2Patients
@kingscollegelondon.bsky.social
October 19, 2025 at 2:35 PM
👏 Congratulations to our @eortc.org #QualityofLife Group members Veronika Engele & Louis Fox for their great presentations at #ESMO25.
🏅 And well done Veronika Engele for winning the ESMO 2025 Best Poster for Psycho-oncology! 💪
#CancerResearch #GivingVoice2Patients
@kingscollegelondon.bsky.social
🏅 And well done Veronika Engele for winning the ESMO 2025 Best Poster for Psycho-oncology! 💪
#CancerResearch #GivingVoice2Patients
@kingscollegelondon.bsky.social
📢 Today we highlight a critical topic at #ESMO25: Eva Blondeaux presents on discontinuation and attrition in first-line RCTs for solid tumors.
What do these trends mean for trial design and patient outcomes?
Don't miss it! 🕥 10:45–10:50
#CancerResearch #EORTC #Oncology
What do these trends mean for trial design and patient outcomes?
Don't miss it! 🕥 10:45–10:50
#CancerResearch #EORTC #Oncology
October 20, 2025 at 8:31 AM
📢 Today we highlight a critical topic at #ESMO25: Eva Blondeaux presents on discontinuation and attrition in first-line RCTs for solid tumors.
What do these trends mean for trial design and patient outcomes?
Don't miss it! 🕥 10:45–10:50
#CancerResearch #EORTC #Oncology
What do these trends mean for trial design and patient outcomes?
Don't miss it! 🕥 10:45–10:50
#CancerResearch #EORTC #Oncology
Reposted by European Organisation for Research and Treatment of Cancer
CSO was at #ESMO2025 today, hosting a symposium to discuss our work in advancing patient-centred cancer care, and how best to engage colleagues and the broader community in Europe and beyond.
#CommonSenseOncology #CancerCare
#CommonSenseOncology #CancerCare
October 17, 2025 at 8:04 PM
CSO was at #ESMO2025 today, hosting a symposium to discuss our work in advancing patient-centred cancer care, and how best to engage colleagues and the broader community in Europe and beyond.
#CommonSenseOncology #CancerCare
#CommonSenseOncology #CancerCare
👉 We continue this exciting day at #ESMO25 with a spotlight on patient engagement!
Iryna Shakhnenko presents the EORTC framework, shaped by patients and professionals, to boost collaboration and improve research outcomes.
📢 Don't miss it!
#Oncology #PatientEngagement #EORTC
Iryna Shakhnenko presents the EORTC framework, shaped by patients and professionals, to boost collaboration and improve research outcomes.
📢 Don't miss it!
#Oncology #PatientEngagement #EORTC
October 19, 2025 at 10:15 AM
👉 We continue this exciting day at #ESMO25 with a spotlight on patient engagement!
Iryna Shakhnenko presents the EORTC framework, shaped by patients and professionals, to boost collaboration and improve research outcomes.
📢 Don't miss it!
#Oncology #PatientEngagement #EORTC
Iryna Shakhnenko presents the EORTC framework, shaped by patients and professionals, to boost collaboration and improve research outcomes.
📢 Don't miss it!
#Oncology #PatientEngagement #EORTC
👏 Well done to Denis Lacombe for a compelling session today at #ESMO25!
Together, we’re shaping a future of cancer research that’s smarter and more inclusive.
#EORTC #CancerResearch #DEI #ClinicalTrials @myesmo.bsky.social
Together, we’re shaping a future of cancer research that’s smarter and more inclusive.
#EORTC #CancerResearch #DEI #ClinicalTrials @myesmo.bsky.social
October 19, 2025 at 8:51 AM
👏 Well done to Denis Lacombe for a compelling session today at #ESMO25!
Together, we’re shaping a future of cancer research that’s smarter and more inclusive.
#EORTC #CancerResearch #DEI #ClinicalTrials @myesmo.bsky.social
Together, we’re shaping a future of cancer research that’s smarter and more inclusive.
#EORTC #CancerResearch #DEI #ClinicalTrials @myesmo.bsky.social
Today at #ESMO25, EORTC CEO Denis Lacombe speaks on two key challenges in cancer research:
➡️ Are we using therapies optimally in real-world care?
➡️ Are clinical trials truly inclusive of all patients?
Two sessions, one goal: research that’s both effective and equitable.
#ClinicalTrials #DEI
➡️ Are we using therapies optimally in real-world care?
➡️ Are clinical trials truly inclusive of all patients?
Two sessions, one goal: research that’s both effective and equitable.
#ClinicalTrials #DEI
October 19, 2025 at 6:31 AM
Today at #ESMO25, EORTC CEO Denis Lacombe speaks on two key challenges in cancer research:
➡️ Are we using therapies optimally in real-world care?
➡️ Are clinical trials truly inclusive of all patients?
Two sessions, one goal: research that’s both effective and equitable.
#ClinicalTrials #DEI
➡️ Are we using therapies optimally in real-world care?
➡️ Are clinical trials truly inclusive of all patients?
Two sessions, one goal: research that’s both effective and equitable.
#ClinicalTrials #DEI
🚨 Big news from #EANO2025!
Final #CATNON results show adding 12 cycles of temozolomide after radiotherapy doubles survival in IDH-mutant anaplastic astrocytoma: 12.5 vs 6 years.
🌍 A global academic effort in rare cancers.
🔗 Full story: www.eortc.org/blog/2025/10...
@eanoassociation.bsky.social
Final #CATNON results show adding 12 cycles of temozolomide after radiotherapy doubles survival in IDH-mutant anaplastic astrocytoma: 12.5 vs 6 years.
🌍 A global academic effort in rare cancers.
🔗 Full story: www.eortc.org/blog/2025/10...
@eanoassociation.bsky.social
October 18, 2025 at 9:58 AM
🚨 Big news from #EANO2025!
Final #CATNON results show adding 12 cycles of temozolomide after radiotherapy doubles survival in IDH-mutant anaplastic astrocytoma: 12.5 vs 6 years.
🌍 A global academic effort in rare cancers.
🔗 Full story: www.eortc.org/blog/2025/10...
@eanoassociation.bsky.social
Final #CATNON results show adding 12 cycles of temozolomide after radiotherapy doubles survival in IDH-mutant anaplastic astrocytoma: 12.5 vs 6 years.
🌍 A global academic effort in rare cancers.
🔗 Full story: www.eortc.org/blog/2025/10...
@eanoassociation.bsky.social
👏 Huge congrats to Madeline Pe for her fantastic presentation at #ESMO25!
Sharing key outcomes from the SISAQOL-IMI initiative and putting patient voices at the heart of cancer research.
Proud moment for EORTC! 📸
#QualityOfLife #EORTC #CancerResearch #GivingVoice2Patients @qol.eortc.org
Sharing key outcomes from the SISAQOL-IMI initiative and putting patient voices at the heart of cancer research.
Proud moment for EORTC! 📸
#QualityOfLife #EORTC #CancerResearch #GivingVoice2Patients @qol.eortc.org
October 17, 2025 at 3:38 PM
👏 Huge congrats to Madeline Pe for her fantastic presentation at #ESMO25!
Sharing key outcomes from the SISAQOL-IMI initiative and putting patient voices at the heart of cancer research.
Proud moment for EORTC! 📸
#QualityOfLife #EORTC #CancerResearch #GivingVoice2Patients @qol.eortc.org
Sharing key outcomes from the SISAQOL-IMI initiative and putting patient voices at the heart of cancer research.
Proud moment for EORTC! 📸
#QualityOfLife #EORTC #CancerResearch #GivingVoice2Patients @qol.eortc.org